Ethyl eicosapentaenoic acid - Amarin

Drug Profile

Ethyl eicosapentaenoic acid - Amarin

Alternative Names: AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl; LAX 101c; LAX-101; Miraxion™; Pure EPA; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Vascepa

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Scarista
  • Developer Amarin Corporation
  • Class Antidepressants; Antihyperlipidaemics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia
  • Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders

Most Recent Events

  • 14 Nov 2016 Additional efficacy data from the post hoc analysis of the pivotal phase III ANCHOR trial in Hypertriglyceridaemia released by Amarin
  • 20 May 2016 Subgroup analysis of efficacy data from the phase III MARINE trial in Hypertriglyceridaemia released by Amarin Pharma
  • 31 Mar 2016 Amarin Corporation completes enrolment in the phase III REDUCE-IT trial for Hypertriglyceridaemia in USA, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, South Africa, Russia and Ukraine (NCT01492361)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top